Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Long intergenic non-protein coding RNA 2228 (LINC02228), also known as HIKER (hypoxia induced kinase-mediated erythropoietic regulator), is a long non-coding RNA (lncRNA) discovered as a critical regulator of erythropoiesis under hypoxic conditions. LINC02228 is significantly upregulated in patients with chronic mountain sickness (CMS, or Monge's disease) and is essential for the excessive erythropoietic response observed in this condition. Knockdown experiments demonstrate that LINC02228 exerts its effects through modulation of CSNK2B, the regulatory subunit of casein kinase 2, thereby controlling downstream transcriptional programs involved in red blood cell production. Functional in vivo and in vitro data support a central role for LINC02228/HIKER in mediating pathologic erythropoiesis at high altitude, but it is not an established drug target or receptor, nor are there known drugs targeting it directly[1][2][4][6].
Not applicable for drug targeting (functions as a regulatory non-coding RNA)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Long intergenic non-protein coding RNA 2228 (LINC02228).